Clinical Trial

A Study of Ixekizumab (LY2439821) in Children With Juvenile Idiopathic Arthritis Categories of Enthesitis-related Arthritis (Including Juvenile Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The reason for this study is to see if the study drug ixekizumab is safe and effective in children with juvenile idiopathic arthritis (JIA) categories of enthesitis-related arthritis (ERA) (including juvenile onset ankylosing spondylitis \[JoAS\]) and juvenile psoriatic arthritis (JPsA).
Protocol Amendment History 1 change
minor Completion pushed: 2028-04 -> 2029-01 2026-08-13
Trial Details
NCT Number NCT04527380
Lead Sponsor Eli Lilly and Company
Conditions Juvenile Psoriatic Arthritis, Enthesitis Related Arthritis
Enrollment 101 participants
Start Date 2021-04-13
Primary Completion 2024-02-19 (estimated)
Study Completion 2029-01 (estimated)
Updated on ClinicalTrials.gov 2026-08-12